Atkins et al. conducted a phase I study on melanoma, both BRAF-mutated melanoma and BRAF wild type, which showed a tolerable safety profile for an anti-PD-L1 antibody when used together with trametinib and dabrafenib [82]. Here, BRAF is linked to melanoma.